Isidro B Salusky

Title(s)Professor, Pediatrics
SchoolMedicine
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    National University of Buenos Aires, Buenos Aires, ArgentinaMD1971Medicine
    Dr. Pedro de Elizade Hospital, Buenos Aires, ArgentinaResidency Training1975
    Hospital des Enfants Malades, Paris, FranceFellowship1979Pediatric Nephrology
    V.A. Wadsworth Medical Center, Los Angeles, CaliforniaAdvanced Research Fellow1981Nutritional Metabolism
    UCLA Medical Center, Los Angeles, CaliforniaFellowship1982Pediatric Nephrology
    Collapse Awards and Honors
    National Kidney Foundation, Inc.1999President's Award
    American Academy of Pediatrics2017Henry Barnett, M.D. Award
    University of Buenos Aires, Argentina2016Honorary Professor of Pediatrics
    American Society of Nephrology2015The Jack W. Coburn, M.D. Endowed Lectureship

    Collapse Overview 
    Collapse Overview
    Isidro B. Salusky, MD is Distinguished Professor of Pediatrics at the David Geffen School of Medicine at UCLA, Chief of Pediatric Nephrology and Director of the Pediatric Dialysis Program. In 1996, Dr. Salusky established a specific clinic for the assessment of Bone and Mineral metabolism in children with different genetic and systemic disorders.

    Dr. Salusky received his MD degree from National University of Buenos Aires, Buenos Aires, Argentina, and completed pediatric residency training at Dr. Pedro de Elizalde Hospital Pediatrics, Buenos Aires, Argentina. Thereafter, Dr. Salusky completed his fellowship in Pediatric Nephrology from Hospital des Enfants Malades, Paris, France and Pediatric Nephrology, at UCLA 1982 and stayed on as faculty. He is Board Certified in Pediatric Nephrology.

    As a clinical-translational research scientist, he has focused his research efforts on the abnormalities of bone and mineral metabolism that are associated with chronic kidney disease (CKD) in children. Through continuous NIH funding, his group has characterized the features of bone diseases across the stages of CKD, and after renal transplantation. Dr. Salusky has also provided significant groundwork for elucidating the relationship between abnormalities of bone and mineral metabolism and vascular calcifications in children and young adults treated with dialysis. His current efforts are focused on studying the role of FGF23 in the pathogenesis of CKD-Mineral and Bone Disorder. More recently, his group has characterized the role of iron and erythropoietin on FGF23 production in the context of CKD. Such studies led to the current prospective randomized clinical trial, NIH funded, (UO1 DK119950) to assess the effects of an iron based binder on FGF23 levels in children with CKD.

    Dr. Salusky is a international recognized leader in the field of bone and mineral metabolism in children with CKD, his expertise is recognized by national and international societies as a regular invited speaker. In addition, Dr. Salusky, co-chair the development of guidelines for the diagnosis and treatment of the nutritional and mineral abnormalities in children with CKD. He is member of the American Society of Nephrology, Society for Pediatric Research, American Society of Bone and Mineral Research and International Society of Pediatric Nephrology (IPNA). At IPNA, Dr. Salusky has multiple roles as Councilor, Treasury and President. Dr. Salusky is committed to the training of the next generation of physicians-scientists in Pediatric Nephrology.

    Collapse Research 
    Collapse Research Activities and Funding
    Phosphate binder therapy and chronic kidney disease in children
    NIH U01DK122013Jun 15, 2020 - Apr 30, 2025
    Role: Principal Investigator
    UCLA Clinical Translational Science Institute
    NIH UL1TR001881Jul 1, 2016 - May 31, 2021
    Role: Co-Investigator
    Phosphate Binders in Children with Chronic Kidney Disease-Mineral Bone Disorder
    NIH U34DK104619Aug 1, 2015 - Jul 31, 2017
    Role: Principal Investigator
    Translational Research Training in Pediatric Nephrology
    NIH T32DK104687Jul 1, 2015 - Apr 30, 2021
    Role: Principal Investigator
    Role of Parathyroid Hormone in Renal Osteodystrophy
    NIH R01DK067563Feb 15, 2005 - Jan 31, 2012
    Role: Principal Investigator
    UCLA Graduate Training Program in Translational and Clinical Investigation
    NIH K30RR022259Sep 30, 2000 - Aug 26, 2012
    Role: Principal Investigator
    ENDOCHONDRAL BONE FORMATION IN RENAL FAILURE
    NIH R21DK053655Jan 1, 1998 - Dec 31, 1999
    Role: Principal Investigator
    Regulation of Bone Mineralization in Renal Osteodystrophy
    NIH R01DK035423Jan 1, 1986 - Jun 30, 2015
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Correspondence on "Prospective phenotyping of long-term survivors of generalized arterial calcification of infancy (GACI)" by Ferreira et al. Genet Med. 2021 Jun 14. Stern R, Levi DS, Gales B, Rutsch F, Salusky IB. PMID: 34127825.
      View in: PubMed   Mentions:    Fields:    
    2. An ARHGAP25 variant links aberrant Rac1 function to early-onset skeletal fragility. JBMR Plus. 2021 Jul; 5(7):e10509. Mäkitie RE, Henning P, Jiu Y, Kämpe A, Kogan K, Costantini A, Välimäki VV, Medina-Gomez C, Pekkinen M, Salusky IB, Schalin-Jäntti C, Haanpää MK, Rivadeneira F, Bassett JHD, Williams GR, Lerner UH, Pereira RC, Lappalainen P, Mäkitie O. PMID: 34258505.
      View in: PubMed   Mentions:
    3. H. William Schnaper - Life course journey of a true Mensch. Pediatr Nephrol. 2021 Jun; 36(6):1657-1659. Greenbaum L, Norwood V, Brewer E, Smoyer W, Moxey-Mims M, Flynn J, Fivush B, Brophy P, Warady B, Watkins S, Salusky I, Kaskel R. PMID: 33730270.
      View in: PubMed   Mentions:    Fields:    
    4. Characterization of Primary Cilia in Osteoblasts Isolated From Patients With ADPKD and CKD. JBMR Plus. 2021 Apr; 5(4):e10464. Pereira RC, Gitomer BY, Chonchol M, Harris PC, Noche KJ, Salusky IB, Albrecht LV. PMID: 33869988.
      View in: PubMed   Mentions:
    5. Race and Ethnicity Predict Bone Markers and Fracture in Pediatric Patients With Chronic Kidney Disease. J Bone Miner Res. 2021 Feb; 36(2):298-304. Laster M, Denburg M, Okuda Y, Kumar J, Furth S, Warady B, Kalantar-Zadeh K, Norris K, Salusky IB. PMID: 32960469.
      View in: PubMed   Mentions:    Fields:    
    6. Mineral bone disease in autosomal dominant polycystic kidney disease. Kidney Int. 2021 04; 99(4):977-985. Gitomer B, Pereira R, Salusky IB, Stoneback JW, Isakova T, Cai X, Dalrymple LS, Ofsthun N, You Z, Malluche HH, Maddux F, George D, Torres V, Chapman A, Steinman TI, Wolf M, Chonchol M. PMID: 32926884.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    7. Regional variation in bone turnover at the iliac crest versus the greater trochanter. Bone. 2021 02; 143:115604. Hughes-Austin JM, Dwight KD, Ginsberg C, Tipps A, Salusky IB, Pereira RC, Ix JH. PMID: 32827849.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    8. Vitamin C overload may contribute to systemic oxalosis in children receiving dialysis. Pediatr Nephrol. 2021 02; 36(2):435-441. Kennedy SS, Perilloux A, Pereira RC, Handelman G, Wesseling-Perry K, Salusky IB. PMID: 32772326.
      View in: PubMed   Mentions: 1     Fields:    
    9. Phase 1, single-dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of etelcalcetide in pediatric patients with secondary hyperparathyroidism receiving hemodialysis. Pediatr Nephrol. 2021 01; 36(1):133-142. Sohn W, Salusky IB, Schmitt CP, Taylan C, Walle JV, Ngang J, Yan L, Kroenke M, Warady BA. PMID: 32647975.
      View in: PubMed   Mentions:    Fields:    
    10. Nephropathic Cystinosis: A Distinct Form of CKD-Mineral and Bone Disorder that Provides Novel Insights into the Regulation of FGF23. J Am Soc Nephrol. 2020 09; 31(9):2184-2192. Florenzano P, Jimenez M, Ferreira CR, Nesterova G, Roberts MS, Tella SH, Fernandez de Castro L, Gafni RI, Wolf M, Jüppner H, Gales B, Wesseling-Perry K, Markovich D, Gahl WA, Salusky IB, Collins MT. PMID: 32631973.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    11. The Authors Reply. Kidney Int Rep. 2020 Jul; 5(7):1119-1120. Sharma S, Hanudel MR, Ix JH, Salusky IB, Ganz T, Nguyen KL. PMID: 32647775.
      View in: PubMed   Mentions:
    12. Measurement of serum phosphate levels using a mobile sensor. Analyst. 2020 Mar 02; 145(5):1841-1848. Ray A, Esparza S, Wu D, Hanudel MR, Joung HA, Gales B, Tseng D, Salusky IB, Ozcan A. PMID: 31960836.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    13. Effects of erythropoietin on fibroblast growth factor 23 in mice and humans. Nephrol Dial Transplant. 2019 12 01; 34(12):2057-2065. Hanudel MR, Eisenga MF, Rappaport M, Chua K, Qiao B, Jung G, Gabayan V, Gales B, Ramos G, de Jong MA, van Zanden JJ, de Borst MH, Bakker SJL, Nemeth E, Salusky IB, Gaillard CAJM, Ganz T. PMID: 30007314.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimals
    14. Unraveling the osteocyte in CKD-MBD post-renal transplantation. Kidney Int. 2019 11; 96(5):1059-1061. Laster M, Pereira RC, Salusky IB. PMID: 31648693.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    15. Erythropoietin and Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease Patients. Kidney Int Rep. 2019 Dec; 4(12):1742-1748. Hanudel MR, Salusky IB, Pereira RC, Wang W, You Z, Nowak KL, Brosnahan GM, Torres VE, Chapman AB, Perrone RD, Steinman TI, Bae KT, Gitomer BY, Chonchol MB. PMID: 31844811.
      View in: PubMed   Mentions:
    16. Elevated Fibroblast Growth Factor 23 Levels Are Associated With Greater Diastolic Dysfunction in ESRD. Kidney Int Rep. 2019 Dec; 4(12):1748-1751. Sharma S, Hanudel MR, Ix JH, Salusky IB, Ganz T, Nguyen KL. PMID: 31844812.
      View in: PubMed   Mentions:
    17. Vitamin D sterols increase FGF23 expression by stimulating osteoblast and osteocyte maturation in CKD bone. Bone. 2019 10; 127:626-634. Pereira RC, Salusky IB, Bowen RE, Freymiller EG, Wesseling-Perry K. PMID: 31377240.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    18. Serum albumin and hospitalization among pediatric patients with end-stage renal disease who started dialysis therapy. Pediatr Nephrol. 2019 10; 34(10):1799-1809. Okuda Y, Obi Y, Streja E, Laster M, Rhee C, Langman CB, Jernigan SM, Salusky IB, Tentori F, Schreiber MJ, Brunelli SM, Kalantar-Zadeh K. PMID: 31218394.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    19. Racial differences in bone histomorphometry in children and young adults treated with dialysis. Bone. 2019 10; 127:114-119. Laster M, Pereira RC, Salusky IB. PMID: 31181383.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    20. Mechanism of Action and Clinical Attributes of Auryxia® (Ferric Citrate). Drugs. 2019 Jun; 79(9):957-968. Ganz T, Bino A, Salusky IB. PMID: 31134521.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    21. Correction to: An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to Sohn WY, Portale AA, Salusky IB, Zhang H, Yan LL, Ertik B, Shahinfar S, Lee E, Dehmel B, Warady BA. PMID: 30536181.
      View in: PubMed   Mentions:    Fields:    
    22. Non-renal-Related Mechanisms of FGF23 Pathophysiology. Curr Osteoporos Rep. 2018 12; 16(6):724-729. Hanudel MR, Laster M, Salusky IB. PMID: 30353318.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    23. Impaired osteocyte maturation in the pathogenesis of renal osteodystrophy. Kidney Int. 2018 11; 94(5):1002-1012. Pereira RC, Salusky IB, Roschger P, Klaushofer K, Yadin O, Freymiller EG, Bowen R, Delany AM, Fratzl-Zelman N, Wesseling-Perry K. PMID: 30348285.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    24. Racial-ethnic differences in chronic kidney disease-mineral bone disorder in youth on dialysis. Pediatr Nephrol. 2019 01; 34(1):107-115. Laster M, Soohoo M, Streja E, Elashoff R, Jernigan S, Langman CB, Norris KC, Salusky IB, Kalantar-Zadeh K. PMID: 30267239.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    25. An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to Sohn WY, Portale AA, Salusky IB, Zhang H, Yan LL, Ertik B, Shahinfar S, Lee E, Dehmel B, Warady BA. PMID: 30141180.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    26. Skeletal Consequences of Nephropathic Cystinosis. J Bone Miner Res. 2018 10; 33(10):1870-1880. Florenzano P, Ferreira C, Nesterova G, Roberts MS, Tella SH, de Castro LF, Brown SM, Whitaker A, Pereira RC, Bulas D, Gafni RI, Salusky IB, Gahl WA, Collins MT. PMID: 29905968.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    27. Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients. Pediatr Nephrol. 2018 11; 33(11):2137-2142. Hanudel MR, Laster M, Ramos G, Gales B, Salusky IB. PMID: 29956006.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    28. Levels of the erythropoietin-responsive hormone erythroferrone in mice and humans with chronic kidney disease. Haematologica. 2018 04; 103(4):e141-e142. Hanudel MR, Rappaport M, Chua K, Gabayan V, Qiao B, Jung G, Salusky IB, Ganz T, Nemeth E. PMID: 29419424.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimals
    29. Erratum to "Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease" [Bone, 45(6) (2009) 1161-1168]. Bone. 2018 03; 108:210-211. Pereira RC, Juppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K. PMID: 29290423.
      View in: PubMed   Mentions:    Fields:    
    30. FGF23 and Left Ventricular Hypertrophy in Children with CKD. Clin J Am Soc Nephrol. 2018 01 06; 13(1):45-52. Mitsnefes MM, Betoko A, Schneider MF, Salusky IB, Wolf MS, Jüppner H, Warady BA, Furth SL, Portale AA. PMID: 29025789.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    31. Development of a translational research pathway at the David Geffen School of Medicine University of California, Los Angeles. Int J Med Educ. 2017 Sep 22; 8:334-335. Demyan L, Harview C, Miller E, Wilkerson L, Salusky IB. PMID: 28949298.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    32. Erythropoietin stimulates murine and human fibroblast growth factor-23, revealing novel roles for bone and bone marrow. Haematologica. 2017 11; 102(11):e427-e430. Clinkenbeard EL, Hanudel MR, Stayrook KR, Appaiah HN, Farrow EG, Cass TA, Summers LJ, Ip CS, Hum JM, Thomas JC, Ivan M, Richine BM, Chan RJ, Clemens TL, Schipani E, Sabbagh Y, Xu L, Srour EF, Alvarez MB, Kacena MA, Salusky IB, Ganz T, Nemeth E, White KE. PMID: 28818868.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimalsCells
    33. Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2017 Sep 07; 12(9):1461-1469. Chonchol M, Gitomer B, Isakova T, Cai X, Salusky I, Pereira R, Abebe K, Torres V, Steinman TI, Grantham JJ, Chapman AB, Schrier RW, Wolf M. PMID: 28705885.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    34. Treatment of Pediatric Chronic Kidney Disease-Mineral and Bone Disorder. Curr Osteoporos Rep. 2017 06; 15(3):198-206. Hanudel MR, Salusky IB. PMID: 28455644.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    35. Fractures and Osteomalacia in a Patient Treated With Frequent Home Hemodialysis. Am J Kidney Dis. 2017 Sep; 70(3):445-448. Hanudel MR, Froch L, Gales B, Jüppner H, Salusky IB. PMID: 28495360.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    36. Increased serum hepcidin contributes to the anemia of chronic kidney disease in a murine model. Haematologica. 2017 03; 102(3):e85-e88. Hanudel MR, Rappaport M, Gabayan V, Jung G, Salusky IB, Nemeth E, Ganz T, Zaritsky J. PMID: 27884972.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    37. Fibroblast growth factor 23: fueling the fire. Kidney Int. 2016 11; 90(5):928-930. Hanudel M, Jüppner H, Salusky IB. PMID: 27742194.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    38. Racial-ethnic disparities in mortality and kidney transplant outcomes among pediatric dialysis patients. Pediatr Nephrol. 2017 04; 32(4):685-695. Laster M, Soohoo M, Hall C, Streja E, Rhee CM, Ravel VA, Reddy U, Norris KC, Salusky IB, Kalantar-Zadeh K. PMID: 27796622.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    39. Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice. Am J Physiol Renal Physiol. 2016 12 01; 311(6):F1369-F1377. Hanudel MR, Chua K, Rappaport M, Gabayan V, Valore E, Goltzman D, Ganz T, Nemeth E, Salusky IB. PMID: 27733366.
      View in: PubMed   Mentions: 22     Fields:    Translation:Animals
    40. Fibroblast Growth Factor 23 and Risk of CKD Progression in Children. Clin J Am Soc Nephrol. 2016 11 07; 11(11):1989-1998. Portale AA, Wolf MS, Messinger S, Perwad F, Jüppner H, Warady BA, Furth SL, Salusky IB. PMID: 27561289.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    41. MRI with ferumoxytol: A single center experience of safety across the age spectrum. J Magn Reson Imaging. 2017 03; 45(3):804-812. Nguyen KL, Yoshida T, Han F, Ayad I, Reemtsen BL, Salusky IB, Satou GM, Hu P, Finn JP. PMID: 27480885.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    42. Correction: Bone Canopies in Pediatric Renal Osteodystrophy. PLoS One. 2016; 11(5):e0155663. Pereira RC, Andersen TL, Friedman PA, Tumber N, Salusky IB, Wesseling-Perry K. PMID: 27167735.
      View in: PubMed   Mentions:    Fields:    
    43. Contrast-enhanced magnetic resonance venography in pediatric patients with chronic kidney disease: initial experience with ferumoxytol. Pediatr Radiol. 2016 Aug; 46(9):1332-40. Luhar A, Khan S, Finn JP, Ghahremani S, Griggs R, Zaritsky J, Salusky I, Hall TR. PMID: 27059620.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    44. Bone Canopies in Pediatric Renal Osteodystrophy. PLoS One. 2016; 11(4):e0152871. Pereira RC, Andersen TL, Friedman PA, Tumber N, Salusky IB, Wesseling-Perry K. PMID: 27045269.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    45. Combining exercise and growth hormone therapy: how can we translate from animal models to chronic kidney disease children? Nephrol Dial Transplant. 2016 08; 31(8):1191-4. Bacchetta J, Salusky IB. PMID: 26908776.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    46. Micro-CT in the Assessment of Pediatric Renal Osteodystrophy by Bone Histomorphometry. Clin J Am Soc Nephrol. 2016 Mar 07; 11(3):481-7. Pereira RC, Bischoff DS, Yamaguchi D, Salusky IB, Wesseling-Perry K. PMID: 26712809.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    47. Effects of acute kidney injury and chronic hypoxemia on fibroblast growth factor 23 levels in pediatric cardiac surgery patients. Pediatr Nephrol. 2016 Apr; 31(4):661-9. Hanudel MR, Wesseling-Perry K, Gales B, Ramos G, Campbell V, Ethridge K, Scotti M, Elashoff DA, Alejos J, Reemtsen B, Salusky IB. PMID: 26525200.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    48. Altered Osteocyte-Specific Protein Expression in Bone after Childhood Solid Organ Transplantation. PLoS One. 2015; 10(9):e0138156. Pereira RC, Valta H, Tumber N, Salusky IB, Jalanko H, Mäkitie O, Wesseling Perry K. PMID: 26390291.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    49. Fracture Burden and Risk Factors in Childhood CKD: Results from the CKiD Cohort Study. J Am Soc Nephrol. 2016 Feb; 27(2):543-50. Denburg MR, Kumar J, Jemielita T, Brooks ER, Skversky A, Portale AA, Salusky IB, Warady BA, Furth SL, Leonard MB. PMID: 26139439.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    50. Osteocytic protein expression response to doxercalciferol therapy in pediatric dialysis patients. PLoS One. 2015; 10(3):e0120856. Pereira RC, Jüppner H, Gales B, Salusky IB, Wesseling-Perry K. PMID: 25774916.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    51. Dr. Ira Greifer. Pediatr Nephrol. 2015 Apr; 30(4):699-700. Kaskel F, Salusky IB. PMID: 25620539.
      View in: PubMed   Mentions:    Fields:    
    52. Antibacterial responses by peritoneal macrophages are enhanced following vitamin D supplementation. PLoS One. 2014; 9(12):e116530. Bacchetta J, Chun RF, Gales B, Zaritsky JJ, Leroy S, Wesseling-Perry K, Boregaard N, Rastogi A, Salusky IB, Hewison M. PMID: 25549329.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    53. Primary osteoblast-like cells from patients with end-stage kidney disease reflect gene expression, proliferation, and mineralization characteristics ex vivo. Kidney Int. 2015 Mar; 87(3):593-601. Pereira RC, Delany AM, Khouzam NM, Bowen RE, Freymiller EG, Salusky IB, Wesseling-Perry K. PMID: 25354236.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    54. Four-dimensional, multiphase, steady-state imaging with contrast enhancement (MUSIC) in the heart: a feasibility study in children. Magn Reson Med. 2015 Oct; 74(4):1042-9. Han F, Rapacchi S, Khan S, Ayad I, Salusky I, Gabriel S, Plotnik A, Finn JP, Hu P. PMID: 25302932.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    55. High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohort. Pediatr Nephrol. 2015 Mar; 30(3):515-21. Nayak AB, Luhar A, Hanudel M, Gales B, Hall TR, Finn JP, Salusky IB, Zaritsky J. PMID: 25212105.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    56. Cortical and trabecular bone in pediatric end-stage kidney disease. Pediatr Nephrol. 2015 Mar; 30(3):497-502. Carvalho CG, Pereira RC, Gales B, Salusky IB, Wesseling-Perry K. PMID: 25185885.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    57. The role of bone in CKD-mediated mineral and vascular disease. Pediatr Nephrol. 2015 Sep; 30(9):1379-88. Khouzam NM, Wesseling-Perry K, Salusky IB. PMID: 25168424.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    58. Lack of FGF23 response to acute changes in serum calcium and PTH in humans. J Clin Endocrinol Metab. 2014 Oct; 99(10):E1951-6. Wesseling-Perry K, Wang H, Elashoff R, Gales B, Jüppner H, Salusky IB. PMID: 25062462.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    59. The accuracy of a continuous volumetric balancing system in pediatric continuous renal replacement therapy. Int J Artif Organs. 2014 Mar; 37(3):215-21. Hanudel MR, Salusky IB, Zaritsky JJ. PMID: 24744166.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    60. FGF23 protein expression in coronary arteries is associated with impaired kidney function. Nephrol Dial Transplant. 2014 Aug; 29(8):1525-32. van Venrooij NA, Pereira RC, Tintut Y, Fishbein MC, Tumber N, Demer LL, Salusky IB, Wesseling-Perry K. PMID: 24459137.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    61. Disordered FGF23 and mineral metabolism in children with CKD. Clin J Am Soc Nephrol. 2014 Feb; 9(2):344-53. Portale AA, Wolf M, Jüppner H, Messinger S, Kumar J, Wesseling-Perry K, Schwartz GJ, Furth SL, Warady BA, Salusky IB. PMID: 24311704.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    62. Suppression of iron-regulatory hepcidin by vitamin D. J Am Soc Nephrol. 2014 Mar; 25(3):564-72. Bacchetta J, Zaritsky JJ, Sea JL, Chun RF, Lisse TS, Zavala K, Nayak A, Wesseling-Perry K, Westerman M, Hollis BW, Salusky IB, Hewison M. PMID: 24204002.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansAnimalsCells
    63. Short daily hemodialysis is associated with lower plasma FGF23 levels when compared with conventional hemodialysis. Nephrol Dial Transplant. 2014 Feb; 29(2):437-41. Zaritsky J, Rastogi A, Fischmann G, Yan J, Kleinman K, Chow G, Gales B, Salusky IB, Wesseling-Perry K. PMID: 24009282.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    64. FGF23 and mineral metabolism in the early post-renal transplantation period. Pediatr Nephrol. 2013 Nov; 28(11):2207-15. Wesseling-Perry K, Pereira RC, Tsai E, Ettenger R, Jüppner H, Salusky IB. PMID: 23852336.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    65. The skeletal consequences of growth hormone therapy in dialyzed children: a randomized trial. Clin J Am Soc Nephrol. 2013 May; 8(5):824-32. Bacchetta J, Wesseling-Perry K, Kuizon B, Pereira RC, Gales B, Wang HJ, Elashoff R, Salusky IB. PMID: 23559676.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    66. Chronic kidney disease: mineral and bone disorder in children. Semin Nephrol. 2013 Mar; 33(2):169-79. Wesseling-Perry K, Salusky IB. PMID: 23465503.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    67. Idiopathic juvenile osteoporosis: a cross-sectional single-centre experience with bone histomorphometry and quantitative computed tomography. Pediatr Rheumatol Online J. 2013; 11:6. Bacchetta J, Wesseling-Perry K, Gilsanz V, Gales B, Pereira RC, Salusky IB. PMID: 23418950.
      View in: PubMed   Mentions: 6     Fields:    
    68. Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children. Pediatr Nephrol. 2013 Apr; 28(4):617-25. Wesseling-Perry K, Salusky IB. PMID: 23381010.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    69. Correlates of parathyroid hormone concentration in hemodialysis patients. Nephrol Dial Transplant. 2013 Jun; 28(6):1516-25. Li J, Molnar MZ, Zaritsky JJ, Sim JJ, Streja E, Kovesdy CP, Salusky I, Kalantar-Zadeh K. PMID: 23348879.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    70. Clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of mineral and bone disorders in chronic kidney disease (CKD-MBD) in adults. Nefrologia. 2013; 33 Suppl 1:1-28. Bellorin-Font E, Ambrosoni P, Carlini RG, Carvalho AB, Correa-Rotter R, Cueto-Manzano A, Jara A, Jorgetti V, Negri AL, Negri A, Olaizola I, Salusky I, Slatopolsky E, Weisinger JR, Comité de Metabolismo Mineral y Óseo , Sociedad Latinoamericana de Nefrología e Hipertensión (SLANH) . PMID: 23629678.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    71. Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes. J Bone Miner Res. 2013 Jan; 28(1):46-55. Bacchetta J, Sea JL, Chun RF, Lisse TS, Wesseling-Perry K, Gales B, Adams JS, Salusky IB, Hewison M. PMID: 22886720.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansCells
    72. Beyond mineral metabolism, is there an interplay between FGF23 and vitamin D in innate immunity? Pediatr Nephrol. 2013 Apr; 28(4):577-82. Bacchetta J, Salusky IB, Hewison M. PMID: 23117582.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    73. Nutritional vitamin D use in chronic kidney disease: a survey of pediatric nephrologists. Pediatr Nephrol. 2013 Feb; 28(2):265-75. Griffin LM, Denburg MR, Shults J, Furth SL, Salusky IB, Hwang W, Leonard MB. PMID: 23086591.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    74. Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysis. Pharmacoepidemiol Drug Saf. 2012 Nov; 21(11):1232-9. Miller JE, Molnar MZ, Kovesdy CP, Zaritsky JJ, Streja E, Salusky I, Arah OA, Kalantar-Zadeh K. PMID: 22996597.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    75. Association of pre-kidney transplant markers of mineral and bone disorder with post-transplant outcomes. Clin J Am Soc Nephrol. 2012 Nov; 7(11):1859-71. Molnar MZ, Kovesdy CP, Mucsi I, Salusky IB, Kalantar-Zadeh K. PMID: 22956265.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    76. The consequences of chronic kidney disease on bone metabolism and growth in children. Nephrol Dial Transplant. 2012 Aug; 27(8):3063-71. Bacchetta J, Harambat J, Cochat P, Salusky IB, Wesseling-Perry K. PMID: 22851629.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    77. An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects. Pediatr Nephrol. 2012 Oct; 27(10):1953-9. Padhi D, Langman CB, Fathallah-Shaykh S, Warady BA, Salusky IB, Lee E, Wang C, Posvar E. PMID: 22639045.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    78. Effects of frequent hemodialysis on measures of CKD mineral and bone disorder. J Am Soc Nephrol. 2012 Apr; 23(4):727-38. Daugirdas JT, Chertow GM, Larive B, Pierratos A, Greene T, Ayus JC, Kendrick CA, James SH, Miller BW, Schulman G, Salusky IB, Kliger AS, Frequent Hemodialysis Network (FHN) Trial Group . PMID: 22362907.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    79. Uric acid and IGF1 as possible determinants of FGF23 metabolism in children with normal renal function. Pediatr Nephrol. 2012 Jul; 27(7):1131-8. Bacchetta J, Cochat P, Salusky IB, Wesseling-Perry K. PMID: 22311343.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    80. Evaluation of hypophosphatemia: lessons from patients with genetic disorders. Am J Kidney Dis. 2012 Jan; 59(1):152-9. Bacchetta J, Salusky IB. PMID: 22075221.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    81. Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol. 2012 Jan; 7(1):146-52. Wesseling-Perry K, Pereira RC, Tseng CH, Elashoff R, Zaritsky JJ, Yadin O, Sahney S, Gales B, Jüppner H, Salusky IB. PMID: 22052943.
      View in: PubMed   Mentions: 68     Fields:    Translation:Humans
    82. Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23? Nephrol Dial Transplant. 2011 Nov; 26(11):3779-84. Wesseling-Perry K, Tsai EW, Ettenger RB, Jüppner H, Salusky IB. PMID: 21441401.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    83. FGF-23: More than a regulator of renal phosphate handling? J Bone Miner Res. 2010 Oct; 25(10):2091-7. Jüppner H, Wolf M, Salusky IB. PMID: 20593414.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    84. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int. 2011 Jan; 79(1):112-9. Wesseling-Perry K, Pereira RC, Sahney S, Gales B, Wang HJ, Elashoff R, Jüppner H, Salusky IB. PMID: 20861820.
      View in: PubMed   Mentions: 67     Fields:    Translation:Humans
    85. Trabecular bone volume and osteoprotegerin expression in uremic rats given high calcium. Pediatr Nephrol. 2010 Nov; 25(11):2311-9. Rianthavorn P, Ettenger RB, Salusky IB, Kuizon BD. PMID: 20676692.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    86. Value of the new bone classification system in pediatric renal osteodystrophy. Clin J Am Soc Nephrol. 2010 Oct; 5(10):1860-6. Bakkaloglu SA, Wesseling-Perry K, Pereira RC, Gales B, Wang HJ, Elashoff RM, Salusky IB. PMID: 20634327.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    87. Ironing out the phosphorus problem. Kidney Int. 2010 May; 77(10):845-7. Zaritsky JJ, Salusky IB. PMID: 20431575.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    88. The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84). J Clin Endocrinol Metab. 2010 Jun; 95(6):2772-80. Wesseling-Perry K, Harkins GC, Wang HJ, Elashoff R, Gales B, Horwitz MJ, Stewart AF, Jüppner H, Salusky IB. PMID: 20382692.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    89. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol. 2010 Jun; 5(6):1010-4. Zaritsky J, Young B, Gales B, Wang HJ, Rastogi A, Westerman M, Nemeth E, Ganz T, Salusky IB. PMID: 20299375.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    90. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab. 2010 Feb; 95(2):578-85. Shimada T, Urakawa I, Isakova T, Yamazaki Y, Epstein M, Wesseling-Perry K, Wolf M, Salusky IB, Jüppner H. PMID: 19965919.
      View in: PubMed   Mentions: 93     Fields:    Translation:Humans
    91. Successful treatment of calcific uremic arteriolopathy in a pediatric dialysis patient. Pediatr Nephrol. 2010 Feb; 25(2):357-62. Amin N, Gonzalez E, Lieber M, Salusky IB, Zaritsky JJ. PMID: 19885686.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    92. Sevelamer carbonate increases serum bicarbonate in pediatric dialysis patients. Pediatr Nephrol. 2010 Feb; 25(2):373-5. Gonzalez E, Schomberg J, Amin N, Salusky IB, Zaritsky J. PMID: 19876653.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    93. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone. 2009 Dec; 45(6):1161-8. Pereira RC, Juppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K. PMID: 19679205.
      View in: PubMed   Mentions: 95     Fields:    Translation:Humans
    94. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int. 2009 Nov; 76(9):977-83. Mehrotra R, Kermah DA, Salusky IB, Wolf MS, Thadhani RI, Chiu YW, Martins D, Adler SG, Norris KC. PMID: 19657329.
      View in: PubMed   Mentions: 68     Fields:    Translation:Humans
    95. Is replacement therapy with nutritional and active forms of vitamin D required in chronic kidney disease mineral and bone disorder? Curr Opin Nephrol Hypertens. 2009 Jul; 18(4):308-14. Wesseling-Perry K, Salusky IB. PMID: 19458529.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    96. Hepcidin--a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol. 2009 Jun; 4(6):1051-6. Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, Ganz T, Rivera S, Nissenson AR, Salusky IB. PMID: 19406957.
      View in: PubMed   Mentions: 97     Fields:    Translation:HumansCTClinical Trials
    97. Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols. Pediatr Nephrol. 2009 Jul; 24(7):1355-61. Wesseling-Perry K, Harkins GC, Wang HJ, Sahney S, Gales B, Elashoff RM, Jüppner H, Salusky IB. PMID: 19301038.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    98. A position statement on kidney disease from powdered infant formula-based melamine exposure in Chinese infants. Pediatr Nephrol. 2009 Jul; 24(7):1263-6. Langman CB, Alon U, Ingelfinger J, Englund M, Saland JM, Somers MJ, Stapleton FB, Sibú NO, Cochat P, Wong W, Eke FU, Satlin L, Salusky I. PMID: 19198884.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansPHPublic Health
    99. Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab. 2009 Feb; 94(2):511-7. Wesseling-Perry K, Pereira RC, Wang H, Elashoff RM, Sahney S, Gales B, Jüppner H, Salusky IB. PMID: 19050056.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    100. Technical approach to iliac crest biopsy. Clin J Am Soc Nephrol. 2008 Nov; 3 Suppl 3:S164-9. Hernandez JD, Wesseling K, Pereira R, Gales B, Harrison R, Salusky IB. PMID: 18988702.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    101. Lost in translation? Pediatr Res. 2008 Sep; 64(3):225. Salusky IB, Cohen P. PMID: 18714199.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    102. Vascular access complications in long-term pediatric hemodialysis patients. Pediatr Nephrol. 2008 Nov; 23(11):2061-5. Zaritsky JJ, Salusky IB, Gales B, Ramos G, Atkinson J, Allsteadt A, Brandt ML, Goldstein SL. PMID: 18712416.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    103. Hypovitaminosis D in chronic kidney disease. Clin J Am Soc Nephrol. 2008 Jul; 3(4):1144-51. Mehrotra R, Kermah D, Budoff M, Salusky IB, Mao SS, Gao YL, Takasu J, Adler S, Norris K. PMID: 18417740.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    104. Gram-negative peritonitis in children undergoing long-term peritoneal dialysis. Am J Kidney Dis. 2008 Mar; 51(3):455-62. Zurowska A, Feneberg R, Warady BA, Zimmering M, Monteverde M, Testa S, Calyskan S, Drozdz D, Salusky I, Kemper MJ, Ekim M, Verrina E, Misselwitz J, Schaefer F. PMID: 18295061.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    105. Chronic kidney disease mineral and bone disorder in children. Pediatr Nephrol. 2008 Feb; 23(2):195-207. Wesseling K, Bakkaloglu S, Salusky I. PMID: 18046581.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    106. Vitamin D therapy in children on dialysis. Perit Dial Int. 2007 Nov-Dec; 27(6):651-3. Wesseling K, Salusky IB. PMID: 17984426.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    107. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis. Am J Kidney Dis. 2007 Jun; 49(6):814-23. Greenbaum LA, Benador N, Goldstein SL, Paredes A, Melnick JZ, Mattingly S, Amdahl M, Williams LA, Salusky IB. PMID: 17533024.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    108. Osteomalacia in a hemodialysis patient receiving an active vitamin D sterol. Nat Clin Pract Nephrol. 2007 Apr; 3(4):227-32. Hernandez JD, Wesseling K, Boechat MI, Gales B, Salusky IB. PMID: 17389892.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    109. A new era in phosphate binder therapy: what are the options? Kidney Int Suppl. 2006 Dec; (105):S10-5. Salusky IB. PMID: 17136110.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    110. Current treatment options in secondary hyperparathyroidism. Nephrol Dial Transplant. 2006 Oct; 21(10):2986-7; author reply 2989-90. Wesseling K, Salusky IB. PMID: 16861736.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    111. Report of an NIH task force on research priorities in chronic kidney disease in children. Pediatr Nephrol. 2006 Jan; 21(1):14-25. Chesney RW, Brewer E, Moxey-Mims M, Watkins S, Furth SL, Harmon WE, Fine RN, Portman RJ, Warady BA, Salusky IB, Langman CB, Gipson D, Scheidt P, Feldman H, Kaskel FJ, Siegel NJ. PMID: 16252095.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    112. Role of parathyroid hormone and therapy with active vitamin D sterols in renal osteodystrophy. Semin Dial. 2005 Jul-Aug; 18(4):290-5. Hernandez JD, Wesseling K, Salusky IB. PMID: 16076350.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    113. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. J Am Soc Nephrol. 2005 Aug; 16(8):2501-8. Salusky IB, Goodman WG, Sahney S, Gales B, Perilloux A, Wang HJ, Elashoff RM, Jüppner H. PMID: 15944337.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    114. Calcification of the coronary arteries in the absence of atherosclerotic plaque. Mayo Clin Proc. 2005 Jun; 80(6):807-9. Qiao JH, Doherty TM, Fishbein MC, Salusky IB, Luthringer DL, Fitzpatrick LA, Shah PK, Rajavashisth TB. PMID: 15948300.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    115. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis. Pediatr Nephrol. 2005 May; 20(5):622-30. Greenbaum LA, Grenda R, Qiu P, Restaino I, Wojtak A, Paredes A, Benador N, Melnick JZ, Williams LA, Salusky IB. PMID: 15785941.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    116. Are new vitamin D analogues in renal bone disease superior to calcitriol? Pediatr Nephrol. 2005 Mar; 20(3):393-8. Salusky IB. PMID: 15690188.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    117. New PTH assays and renal osteodystrophy. Pediatr Nephrol. 2004 Jul; 19(7):709-13. Salusky IB, Jüppner H. PMID: 15173936.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    118. Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis. 2004 Mar; 43(3):558-65. Martin KJ, Olgaard K, Coburn JW, Coen GM, Fukagawa M, Langman C, Malluche HH, McCarthy JT, Massry SG, Mehls O, Salusky IB, Silver JM, Smogorzewski MT, Slatopolsky EM, McCann L, Bone Turnover Work Group . PMID: 14981615.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    119. Bone histology in steroid-treated children with non-azotemic nephrotic syndrome. Pediatr Nephrol. 2004 Apr; 19(4):400-7. Freundlich M, Jofe M, Goodman WG, Salusky IB. PMID: 14991389.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    120. Special aspects of renal osteodystrophy in children. Semin Nephrol. 2004 Jan; 24(1):69-77. Salusky IB, Kuizon BG, Jüppner H. PMID: 14730512.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    121. Sudden blindness caused by anterior ischemic optic neuropathy in 5 children on continuous peritoneal dialysis. Am J Kidney Dis. 2003 Nov; 42(5):E3-9. Lapeyraque AL, Haddad E, André JL, Brémond-Gignac D, Taylor CM, Rianthavorn P, Salusky IB, Loirat C. PMID: 14582071.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    122. Sevelamer hydrochloride: an effective phosphate binder in dialyzed children. Pediatr Nephrol. 2003 Dec; 18(12):1260-4. Mahdavi H, Kuizon BD, Gales B, Wang HJ, Elashoff RM, Salusky IB. PMID: 14586677.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    123. Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int. 2003 May; 63(5):1801-8. Salusky IB, Goodman WG, Kuizon BD, Lavigne JR, Zahranik RJ, Gales B, Wang HJ, Elashoff RM, Jüppner H. PMID: 12675856.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    124. Bone density measurements in pediatric patients with renal osteodystrophy. Pediatr Nephrol. 2003 Jun; 18(6):554-9. Lima EM, Goodman WG, Kuizon BD, Gales B, Emerick A, Goldin J, Salusky IB. PMID: 12712376.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    125. Outcome of slipped capital femoral epiphysis in renal osteodystrophy. J Pediatr Orthop. 2003 Mar-Apr; 23(2):169-74. Oppenheim WL, Bowen RE, McDonough PW, Funahashi TT, Salusky IB. PMID: 12604945.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    126. Parathyroid hormone (PTH), PTH-derived peptides, and new PTH assays in renal osteodystrophy. Kidney Int. 2003 Jan; 63(1):1-11. Goodman WG, Jüppner H, Salusky IB, Sherrard DJ. PMID: 12472763.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    127. New lessons from old assays: parathyroid hormone (PTH), its receptors, and the potential biological relevance of PTH fragments. Nephrol Dial Transplant. 2002 Oct; 17(10):1731-6. Goodman WG, Salusky IB, Jüppner H. PMID: 12270977.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    128. Cell biology of renal osteodystrophy. Pediatr Nephrol. 2002 Oct; 17(10):777-89. Kuizon BD, Salusky IB. PMID: 12376803.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    129. Clonal chromosomal defects in the molecular pathogenesis of refractory hyperparathyroidism of uremia. J Am Soc Nephrol. 2002 Jun; 13(6):1490-8. Imanishi Y, Tahara H, Palanisamy N, Spitalny S, Salusky IB, Goodman W, Brandi ML, Drüeke TB, Sarfati E, Ureña P, Chaganti RS, Arnold A. PMID: 12039978.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    130. Growth hormone and the skeleton in pediatric renal allograft recipients. Pediatr Nephrol. 2002 May; 17(5):322-8. Sanchez CP, Kuizon BD, Goodman WG, Gales B, Ettenger RB, Boechat MI, Wang Y, Elashoff R, Salusky IB. PMID: 12042887.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    131. Cardiovascular calcification in end-stage renal disease. Nephrol Dial Transplant. 2002 Feb; 17(2):336-9. Salusky IB, Goodman WG. PMID: 11812902.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    132. PTH assays in renal failure. Semin Dial. 2002 Jan-Feb; 15(1):73. Salusky IB. PMID: 11874600.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    133. Adynamic renal osteodystrophy: is there a problem? J Am Soc Nephrol. 2001 Sep; 12(9):1978-1985. Salusky IB, Goodman WG. PMID: 11518793.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    134. Implications of intermittent calcitriol therapy on growth and secondary hyperparathyroidism. Pediatr Nephrol. 2000 Jul; 14(7):641-5. Salusky IB, Goodman WG, Kuizon BD. PMID: 10912534.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals